

WHO Collaborating Centre
for Quality Control of
HIV, HCV, HBsAg and Syphilis In-Vitro Diagnostic Assays

Head of the Collaborating Centre

Dr.(Mrs) Reba Chhabra

Director In-Charge

NIB, NOIDA



WHO Collaborating Centre for Quality Control of HIV, HCV, HBsAg and Syphilis In-Vitro Diagnostic Assays



World Health Organization
South-East Asia

Office Address:

Permanent: World Health House, Indraprastha Estate, Mayapuri, New Delhi-110002, India. www.searo.who.int
Telephone: 88799300/88799301, Office Block, Bahala Singh Road, Connaught Place, New Delhi-110028, India.
Annex - Rm Post Capital Parkview Tower 1, Bua Via Sach Mans, Connaught Place, New Delhi-110001, India.
Tel: 91-11-4204 0000 / 8161, Fax: 91-11-2328 3325

Dr Surinder Singh
Director
Immunodiagnostic Kits & Molecular
Diagnostic Laboratory
National Institute of Biologicals
A-32, Sector-06
Noida - 201309
Uttar Pradesh

In reply please refer to: A20/18/54

Dear Dr Singh,

Subject: Designation of Immunodiagnostic Kits and Molecular diagnostic Laboratory, National Institute of Biologicals as a WHO Collaborating Centre for Quality Control of HIV, HCV, HBsAg and Syphilis in-vitro diagnostic assays (WHO CC No. IND-148)

I am pleased to inform you that the World Health Organization has designated the Immunodiagnostic Kits and Molecular diagnostic Laboratory, National Institute of Biologicals as a WHO Collaborating Centre for Quality Control of HIV, HCV, HBsAg and Syphilis in-vitro diagnostic assays (WHO CC No. IND-148)

As previously agreed, Dr Reba Chhabra will act as Head of the Centre. Should there be any change in the future, I would be grateful if you would inform WHO without delay.

The agreed terms of reference and workplan of the Centre are attached. We wish to emphasize that institutions designated as WHO collaborating centres are expected to implement the agreed workplan in a timely manner and to the highest possible standard of quality. Any issue that may affect the implementation of the agreed workplan should be brought to the attention of the WHO responsible officer, Dr Gaby Henriette Vercauteren, Senior Adviser, HQ/RSS Regulatory Systems Strengthening (HQ/HIS/EMP/RHT/RSS) Tel: + 41 22 791 4728 or email at vercautere@g.who.int. For information on administrative matters, please visit the WHO website <http://www.who.int/collaborating-centres/information/en/>.

We wish to also emphasize that institutions designated as WHO Collaborating Centres must also comply with the attached terms and conditions for WHO collaborating centres. We wish to draw your particular attention to the fact that the WHO name and emblem may only be used by a WHO Collaborating Centre as described in those terms and conditions.

Finally, please note that institutions designated as WHO collaborating centres must complete a short online progress report form once a year. On the anniversary of the designation date, details will be sent to the email address of the Head of the Centre specified in the designation form.

The designation of your institution as a WHO Collaborating Centre will be effective for a period of 4 years from 19 September 2018, and will automatically end on 19 September 2022, unless redesignation has been approved by WHO before that date. During the period of designation, either party may revoke the designation at any time by giving three months advance notice in writing.

Yours sincerely,

Dr Poonam Khetrapal Singh
Regional Director

